anticancer agent 11

Anticancer agent 11 an effective broad-spectrum anticancer agent, exerts its therapeutic potential by suppressing angiogenesis and facilitating the formation of DNA cross-links.

Anticancer agent 110 is an anticancer compound with cytotoxic, antitumor, and antileukemic activity that triggers DNA damage and apoptosis and is used in the study of chronic granulocytic leukemia.

Anticancer agent 111 (compound 11), exhibiting anticancer activity, serves as a potent inhibitor of cytochrome P450, particularly targeting CYP3A4 with an inhibitory concentration (IC50) of 3 μM. It is useful in cancer research [1].

Anticancer agent 114, a dipeptide boronic acid ester, functions as a potent proteasome inhibitor with an oral activity and demonstrates an IC50 of 2.2 nM. It exhibits antiproliferative properties specifically targeting RPMI-8226 cells, making it valuable for research into multiple myeloma [1].

Anticancer Agent 118, an N‑acylated ciprofloxacin derivative, exhibits antibacterial efficacy against Gram-positive strains and antiproliferative effects on prostate PC3 cells, making it a potential candidate for antitumor research [1].

Anticancer agent 113 possesses anticancer activity [1].

Anticancer agent 112[1], serves as a potent agent for cancer research.

Compound 15 (Anticancer agent 119), an N-acylated ciprofloxacin derivative, exhibits antibacterial activity and induces the production of ROS, further promoting apoptosis in cancer cells [1].

Antiproliferative agent-60 (compound 8c), an 11-Azaartemisinin derivative, exhibits outstanding anticancer activity. It demonstrates tumor selectivity up to 32 times higher when compared to normal Hek293 cells. The IC50 values for Antiproliferative agent-60 are 7.7 μM for epidermoid carcinoma (KB), 42.5 μM for HepG2, and 15.5 μM for A549 cells.

Compound 12k (THP-1 MV-4-11 against-1) is a 5-substituted thiazolyl urea anticancer agent with significant inhibitory efficacy against THP-1 MV-4-11 cancer cells, demonstrating IC50 values of 29 nM and 98 nM, respectively.

CL2-MMT-SN38 is a derivative of SN-38, which is a potent anticancer agent and the active metabolite of Irinotecan (CPT-11), a Topoisomerase I inhibitor.

Anticancer agent 36 (compound 11) is a potent anti-microbial and anti-cancer agent, a sulfonylurea derivative. anticancer agent 36 inhibits the microbial growth of Bacillus mycoides, Escherichia coli and Candida albicans (MIC: 0.156 - 0.039 mg mL). Anticancer agent 36 inhibited the growth of A549 cells (IC50: 19.7 μg mL), PC3 cells (IC50: 11.9 μg mL).

Antiproliferative agent-30 (Compound 8g) exhibits broad-spectrum antiproliferative activity, with IC50 values of 0.054 nM, 0.008 nM, and 0.144 nM against HCT-116, K562, and MV-4-11 cancer cell lines, respectively. It inhibits tubulin assembly, FLT3, and Abl1 kinases and shows vascular-disrupting capabilities. Additionally, it displays an anticancer effect against acute myeloid leukemia (AML) with FLT3-ITD-TKD mutations [1].

Compound 156, also referred to as compound 11, is a potent miliusanes-based anticancer agent that demonstrates effective inhibition of human cancer cell growth and exhibits substantial cytotoxicity against gastric cancer cells [1].